PainReform (NASDAQ: PRFX) is one of the best-performing stocks on the public market today, surging in value by 40% on heavy volume.
If you are interested in investing in PainReform stock, you have come to the right place. This article provides all of the key information you need to inform your potential investment, including what the company is, what it does, and what its future investment prospects are.
If you want to buy PRFX shares right now, scroll down to the section below and click on one of the links; these are the best places to buy PainReform stock in the UK and elsewhere.
How & where to buy PainReform shares online
To buy, sell and trade PRFX stock quickly, easily and affordably, click on one of the links below, fill out the required information, then fund your newly-created account. Then, you can purchase all of the shares you want to hold.
So, here are the two best platforms to buy, sell and trade PainReform stock today:
eToro is one of the world's leading multi-asset trading platforms offering some of the lowest commission and fee rates in the industry. It's social copy trading features make it a great choice for those getting started.
Financial company driven by technology and offering all-in-one self-directed investment platform that provides excellent user experience.
What is PainReform?
Incorporated in 2007 and based in Tel Aviv, Israel, it is a clinical-stage specialty pharmaceutical company. PainReform is engaged in the development of therapeutics that provide an extended period of post-surgical pain relief in Israel.
The company’s main treatment candidate is PRF-110, which is a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localised and extended post-operative analgesia. Phase-3 clinical trials are currently underway for the treatment of patients undergoing bunionectomy surgery and hernia repair.
The company is surging in value following heavy volume, and there is speculation that the company’s healthy financials and main product could lead it successfully down the road to commercial success.
Should I buy PRFX stock today?
Investing always carries a degree of risk, and this is especially true of experimental pharmaceutical companies, but if you have conducted your own research and believe PainReform could grow and deliver shareholder value, investing now may not be a bad move.
PRFX price target 2021
Our 12-month PainReform price target is $10.